Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Exonhit

Home Clinical Trial Sponsors and OrganizationsExonhit

Exonhit

CLOSED

Francewww.exonhit.comPrivate

Part of Eurobio-Scientific SA

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

4

1 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Not Applicable

1

25.0%

Phase 2

1

25.0%

Trial Status Distribution

Active, not recruiting

1

25.0%

Completed

3

75.0%

Clinical Trials

Trials sponsored by this organization (4)

Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center

Nov 2011160 participants

A Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 as Adjunctive Therapy to Acetylcholinesterase Inhibitor in Mild to Moderate Alzheimer's Disease

Apr 2008197 participants

Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia

Feb 2008550 participants

A pilot, randomized, double-blind, placebo-controlled, parallel group, multicentre, phase IIa study to determine the clinical safety/tolerability and exploratory efficacy of EHT 0202 (40 and 80 mg bid) as adjunctive therapy to acetylcholinesterase inhibitor over a 3-month period in ambulatory patients suffering from mild to moderate Alzheimer’s Disease (EHT 0202/002 protocol).

Active, not recruiting

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials4
Approvals
News

Back to Organizations